Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saxagliptin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saxagliptin Anhydrous SCHEMBL988028 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8269188 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL882684 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17642049 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL988030 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17168 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL23752173 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8269720 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL14763515 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15579932 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683267-B1 | Antidiabetic compounds | KING ABDULAZIZ UNIVERSITY (SA) | 2020-06-16 | — | — | US | disclosed |
| US-10654800-B1 | Antidiabetic compounds | KING ABDULAZIZ UNIVERISTY (SA) | 2020-05-19 | — | — | US | disclosed |
| EP-2505579-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2505579-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2505579-A2 | Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120088808-A1 | CRYSTAL FORMS OF SAXAGLIPTIN | SANDOZ AG (CH) | 2012-04-12 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20070259927-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-20070259927-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259927-A1 | Remedy for Diabetes | IAPP, DPP4, PNLIP | DPP4 2/4885CYP3A4 2795/4885DPP8 8/4885 |
| US-20120088808-A1 | CRYSTAL FORMS OF SAXAGLIPTIN | DPP4, DPP3, SLC5A1 | DPP4 1/4885CYP3A4 117/4885DPP8 7/4885 |
| US-10654800-B1 | Antidiabetic compounds | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 63/4885DPP8 4/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | DPP4 5/4885CYP3A4 328/4885DPP8 21/4885 |
| US-10683267-B1 | Antidiabetic compounds | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 63/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.